MoonLake Immunotherapeutics - Asset Resilience Ratio
MoonLake Immunotherapeutics (MLTX) has an Asset Resilience Ratio of 14.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how MoonLake Immunotherapeutics's Asset Resilience Ratio has changed over time. Check how strategically is MoonLake Immunotherapeutics's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down MoonLake Immunotherapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MoonLake Immunotherapeutics stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $59.45 Million | 14.01% |
| Total Liquid Assets | $59.45 Million | 14.01% |
Asset Resilience Insights
- Moderate Liquidity: MoonLake Immunotherapeutics has 14.01% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
MoonLake Immunotherapeutics Industry Peers by Asset Resilience Ratio
Compare MoonLake Immunotherapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for MoonLake Immunotherapeutics (2021–2025)
The table below shows the annual Asset Resilience Ratio data for MoonLake Immunotherapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 14.01% | $59.45 Million | $424.43 Million | -41.98pp |
| 2024-12-31 | 55.99% | $267.60 Million | $477.93 Million | +44.63pp |
| 2023-12-31 | 11.36% | $59.84 Million | $526.54 Million | -31.07pp |
| 2022-12-31 | 42.44% | $32.61 Million | $76.84 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $9.68 Million | -- |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more